Q1 Earnings Estimate for MacroGenics Issued By HC Wainwright

MacroGenics, Inc. (NASDAQ:MGNX - Free Report) - HC Wainwright increased their Q1 2025 earnings per share estimates for MacroGenics in a report released on Tuesday, March 25th. HC Wainwright analyst R. Burns now anticipates that the biopharmaceutical company will post earnings per share of ($0.69) for the quarter, up from their prior estimate of ($0.70). HC Wainwright currently has a "Neutral" rating and a $2.00 target price on the stock. The consensus estimate for MacroGenics' current full-year earnings is ($1.06) per share. HC Wainwright also issued estimates for MacroGenics' Q2 2025 earnings at ($0.71) EPS, Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.75) EPS and FY2025 earnings at ($2.89) EPS.

MacroGenics (NASDAQ:MGNX - Get Free Report) last posted its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.02). The firm had revenue of $49.40 million for the quarter, compared to analyst estimates of $34.17 million. MacroGenics had a negative return on equity of 89.42% and a negative net margin of 69.07%.

Separately, StockNews.com cut MacroGenics from a "buy" rating to a "hold" rating in a research note on Friday, March 21st. Nine equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $7.38.

MacroGenics Trading Down 2.0 %

MGNX stock traded down $0.03 during trading on Thursday, reaching $1.24. The stock had a trading volume of 219,071 shares, compared to its average volume of 1,168,734. The firm has a fifty day moving average price of $2.51 and a 200 day moving average price of $3.15. The company has a market capitalization of $77.92 million, a P/E ratio of -0.78 and a beta of 2.12. MacroGenics has a 1-year low of $1.24 and a 1-year high of $19.54.

Institutional Investors Weigh In On MacroGenics

A number of institutional investors have recently made changes to their positions in the company. Wasatch Advisors LP boosted its holdings in MacroGenics by 37.6% in the fourth quarter. Wasatch Advisors LP now owns 3,488,493 shares of the biopharmaceutical company's stock worth $11,338,000 after purchasing an additional 952,691 shares during the period. Frazier Life Sciences Management L.P. grew its position in shares of MacroGenics by 5.5% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 3,175,665 shares of the biopharmaceutical company's stock valued at $10,321,000 after buying an additional 164,938 shares during the last quarter. Geode Capital Management LLC raised its stake in MacroGenics by 1.9% during the fourth quarter. Geode Capital Management LLC now owns 1,433,217 shares of the biopharmaceutical company's stock worth $4,659,000 after acquiring an additional 26,341 shares during the period. Two Sigma Advisers LP lifted its holdings in MacroGenics by 7.1% in the fourth quarter. Two Sigma Advisers LP now owns 1,118,600 shares of the biopharmaceutical company's stock worth $3,635,000 after acquiring an additional 74,596 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC acquired a new position in MacroGenics in the fourth quarter valued at approximately $2,787,000. 96.89% of the stock is currently owned by institutional investors.

About MacroGenics

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.